Page 100 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
• Disease Monitoring In Multiple Myeloma.
Clin Lymphoma Myeloma Leuk. 2023;23(4):244-8. doi: 10.1016/j.clml.2023.01.005.
Hillengass J, Martín T, Puig N, Paiva B, Usmani S, Kumar S, San-Miguel J.
• Time-Dependent Prognostic Value of Serological and Measurable Residual Disease
Assessments after Idecabtagene Vicleucel.
Blood Cancer Discov. 2023;4(5):365-73. doi: 10.1158/2643-3230.BCD-23-0044.
Paiva B, Manrique I, Rytlewski J, Campbell T, Kazanecki CC, Martín N, Anderson LD Jr,
Berdeja JG, Lonial S, Raje NS, Lin Y, Moreau P, San-Miguel JF, Munshi NC, Kaiser SM.
• Large T cell clones expressing immune checkpoints increase during multiple my-
eloma evolution and predict treatment resistance.
Nat Commun. 2023;14(1):5825. doi: 10.1038/s41467-023-41562-6.
Botta C, Pérez C, Larrayoz M, Puig N, Cedena MT, Termini R, Goicoechea I, Rodríguez S,
Zabaleta A, López A, Sarvide S, Blanco L, Papetti DM, Nobile MS, Besozzi D, Gentile M,
Correale P, Siragusa S, Oriol A, González-García ME, Sureda A, de Arriba F, Ríos Tamayo
R, Moraleda JM, Gironella M, Hernández MT, Bargay J, Palomera L, Pérez-Montaña A,
Goldschmidt H, Avet-Loiseau H, Roccaro A, Orfao A, Martínez-López J, Rosiñol L, Lahuer-
ta JJ, Bladé J, Mateos MV, San-Miguel JF, Martínez Climent JA, Paiva B; Programa Para el
Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma (PETHE-
MA/GEM) cooperative group; iMMunocell study group.
• Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored
by residual disease status in myeloma.
Blood. 2023;142(18):1518-28. doi: 10.1182/blood.2022019531.
Rosiñol L, Oriol A, Ríos R, Blanchard MJ, Jarque I, Bargay J, Hernández MT, Cabañas
V, Carrillo-Cruz E, Sureda A, Martínez-López J, Krsnik I, González ME, Casado LF, Mar-
tí JM, Encinas C, de Arriba F, Palomera L, Sampol A, González-Montes Y, Cabezudo
E, Paiva B, Puig N, Cedena MT, de la Cruz J, Mateos MV, San Miguel J, Lahuerta JJ,
Bladé J.
• Impact of treatment effect on MRD and PFS: an aggregate analysis from random-
ized clinical trials in multiple myeloma.
Blood Adv. 2023 Aug 28:bloodadvances.2023010821. doi: 10.1182/bloodadvan-
ces.2023010821. Online ahead of print.
Paiva B, Zherniakova A, Núñez-Córdoba JM, Rodríguez-Otero P, Shi Q, Munshi NC, Durie
B, San-Miguel J.
100